Rare tumor chemotherapy showdown: platinum vs. Non-Platinum
NCT ID NCT04365023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzed data from 168 patients with a rare type of digestive neuroendocrine tumor (well-differentiated grade 3). Researchers compared survival and response rates in patients who received platinum-based chemotherapy versus those who received non-platinum chemotherapy. The goal was to see which approach might work better for these uncommon tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- platinum chemotherapy
- What this could lead to
- If successful, this could help doctors choose better first-line chemotherapy for patients with these rare tumors, potentially improving survival.
- What could go wrong
- This is an observational study, not a controlled trial, so results may not prove one treatment is better. The tumors are rare, making findings less generalizable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gastroenterology and digestive oncology unit - Cochin hospital
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial